Skip to main content

Table 4 Hazard ratios for cancer incidence and mortality by MHT dosea: multivariate analyses

From: The effect of menopausal hormone therapy on gastrointestinal cancer risk and mortality in South Korea: a population-based cohort study

  n Any cancer GI cancer Gastric cancer
HR 95% CI P HR 95% CI P HR 95% CI P
Incidence
DDD no MHT 96,548 1.000 0.4709 1.000 0.0002 1.000 0.0223
 ≤ 100 10,199 1.004 0.893, 1.128 0.9503 0.786 0.617, 1.002 0.0520 0.790 0.529, 1.180 0.2494
 100–300 4423 0.957 0.803, 1.139 0.6189 0.710 0.487, 1.035 0.0746 0.553 0.274, 1.116 0.0982
 300–600 2569 1.031 0.827, 1.284 0.7886 0.488 0.269, 0.884 0.0180 0.476 0.178, 1.278 0.1408
 ≥ 600 2352 0.876 0.681, 1.127 0.3031 0.545 0.292, 1.018 0.0568 0.709 0.293, 1.719 0.4471
Mortality
DDD no MHT 96,548 1.000 0.0052 1.000 0.0064 1.000 0.0264
 ≤ 100 10,199 0.663 0.470, 0.936 0.0194 0.514 0.300, 0.881 0.0156 0.445 0.139, 1.421 0.1718
 100–300 4423 0.891 0.563, 1.410 0.6224 0.798 0.410, 1.553 0.5067 NAb
 300–600 2569 0.852 0.455, 1.595 0.6165 0.481 0.154, 1.503 0.2081 NAb
 ≥ 600 2352 0.113 0.016, 0.803 0.0294 0.213 0.030, 1.521 0.1232 NAb
  n Colorectal cancer Hepatobiliary cancer Pancreas cancer
HR 95% CI P HR 95% CI P HR 95% CI P
Incidence
DDD no MHT 96,548 1.000   0.0069 1.000   0.1765 1.000   0.6680
 ≤ 100 10,199 0.843 0.568, 1.251 0.3970 0.639 0.355, 1.148 0.1338 0.825 0.330, 2.065 0.6813
 100–300 4423 0.643 0.331, 1.249 0.1926 0.866 0.407, 1.845 0.7095 1.538 0.556, 4.252 0.4065
 300–600 2569 0.626 0.258, 1.515 0.2988 0.443 0.110, 1.787 0.2527 NAc - -
 ≥ 600 2352 0.152 0.021, 1.082 0.0600 0.874 0.278, 2.743 0.8174 0.904 0.125, 6.558 0.9203
Mortality
DDD no MHT 96,548 1.000   0.0672 1.000   0.3329 1.000   0.8495
 ≤ 100 10,199 NAb 0.612 0.267, 1.403 0.2464 0.963 0.343, 2.705 0.9429
 100–300 4423 NAb 1.476 0.644, 3.380 0.3574 1.666 2.705, 5.411 0.3957
 300–600 2569 1.403 0.341, 5.762 0.6387 NAb NAb
 ≥ 600 2352 NAb 0.633 0.088, 4.566 0.6505 NAb
  1. Other covariates (age group, income, region, Charlson comorbidity index, and year of study entry) were adjusted in each survival analysis
  2. CI confidence interval, DDD defined daily dose, GI gastrointestinal, HR hazard ratio, MHT menopausal hormone therapy, NA not available
  3. aUsing Landmark analysis (19,543 MHT users vs. 96,548 non-users)
  4. bThere was no death from cancer at the MHT dose
  5. cThere was no cancer diagnosis at the MHT dose
  6. Ptrend